TITLE:
Serum Lipids and Lipokines as Prognostic/Diagnostic Biomarkers in Common Cancers
AUTHORS:
Nikolaos Dogkas, Maria Τrapali, Christine Fountzoula, Georgios Albert Karikas, Petros Karkalousos
KEYWORDS:
Cancer, Total Cholesterol, Triglycerides, HDL, LDL, Resistin, Visfatin
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.12 No.2,
May
26,
2022
ABSTRACT: Total cholesterol (CHOL)
levels have been shown in many studies, to be higher in people with several
types of cancer. Similar results are observed for both triglycerides (TG) and
low-density cholesterol (LDL), as opposed to high-density cholesterol (HDL). Chemotherapy
seems to reduce CHOL and LDL, leading to a reduction. Furthermore, the
recurrence of high levels of CHOL, TG and LDL, as well as low levels of HDL,
after receiving treatment, or when patients appear to have been cured, are
signs of a possible recurrence of the disease. Lipoprotein α (Lpa),
occurs at higher levels in patients than in healthy people, whereas lipokines
resistin and bisfatin, “hormonal” products of adipose tissue exhibited high
levels in cancer cases, compared to control groups.